Geneos Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Geneos Therapeutics's estimated annual revenue is currently $1.6M per year.
- Geneos Therapeutics's estimated revenue per employee is $135,625
- Geneos Therapeutics's total funding is $50M.
Employee Data
- Geneos Therapeutics has 12 Employees.
- Geneos Therapeutics grew their employee count by -25% last year.
Geneos Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Controller | Reveal Email/Phone |
2 | VP, Research and Discovery | Reveal Email/Phone |
3 | VP, Research and Discovery | Reveal Email/Phone |
4 | VP, Quality Assurance - Manufacturing | Reveal Email/Phone |
5 | Chief Operating Officer | Reveal Email/Phone |
6 | Consulting Chief Financial Officer | Reveal Email/Phone |
7 | Consulting Chief Medical Officer | Reveal Email/Phone |
8 | Consulting Chief Business Officer | Reveal Email/Phone |
Geneos Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.6M | 7 | -12% | N/A | N/A |
#2 | $4M | 38 | 81% | N/A | N/A |
#3 | N/A | 76 | 27% | N/A | N/A |
#4 | $0.9M | 5 | 0% | N/A | N/A |
#5 | $1.1M | 8 | 33% | N/A | N/A |
#6 | $10.9M | 61 | 7% | N/A | N/A |
#7 | $0.7M | 9 | 29% | N/A | N/A |
#8 | $4M | 20 | -5% | N/A | N/A |
#9 | $1.7M | 11 | 22% | N/A | N/A |
#10 | $7.6M | 49 | 2% | N/A | N/A |
What Is Geneos Therapeutics?
At Geneos, our passion is to develop personalized therapies to unleash the most powerful force against cancer – your body’s own immune system. Our GT-EPIC Platform is designed to identify relevant neoantigen targets and then design, manufacture, and deliver tumor specific neoantigen-targeted personalized immunotherapies.
keywords:N/A
$50M
Total Funding
12
Number of Employees
$1.6M
Revenue (est)
-25%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Geneos Therapeutics News
At Geneos Therapeutics, we believe that personalized therapies are the future of cancer treatment. Our passion is to develop personalized...
The company intends to use the funds to expand the GT-30 Phase Ib/IIa clinical trial, its pipeline into a new indication, and continued...
Part of the money will expand Geneos' GT-30 Phase Ib/IIa clinical trial for a personalized cancer vaccine, ... Harm Reduction Therapeutics.
Other Companies in Plymouth Meeting
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.3M | 12 | -14% | N/A |
#2 | $1.9M | 12 | 20% | N/A |
#3 | $2M | 13 | 18% | N/A |
#4 | $1M | 15 | 25% | N/A |
#5 | $3.2M | 19 | 6% | N/A |